Results for 'ASCO VF'
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
Feb 11th • 4 mins read
A Field Test of Major Value Frameworks in Chemotherapy of Nasopharyngeal Carcinoma-To Know, Then to Measure
Aug 12th • 10 mins read
Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies
Sep 6th • 20 mins read
Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
Aug 31st • 16 mins read
Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration
Jul 22nd • 12 mins read
Value assessment of oncology drugs using a weighted criterion-based approach
Dec 20th • 15 mins read
First person profile: Supriya G. Mohile, MD, MS: A respected geriatric oncologist, Dr. Mohile has conducted innovative research on improving care for older patients with cancer
Oct 11th • 2 mins read
Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale
Jul 10th • 12 mins read
Clinical benefit of cancer drugs approved in Switzerland 2010–2019
Jun 10th • 35 mins read
Association between control group therapy and magnitude of clinical benefit of cancer drugs
Dec 9th • 20 mins read
Value assessment of PD-1/PD-L1 inhibitors in the treatment of esophageal and gastrointestinal cancers
Apr 21st • 13 mins read
The correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworks
Feb 23rd • 9 mins read
Value assessment of NMPA-approved new cancer drugs for solid cancer in China, 2016-2020
Feb 24th • 8 mins read
Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines
Nov 14th • 21 mins read
US Government Payer-Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action?
Feb 13th • 5 mins read
Medical Oncologists’ Knowledge and Perspectives on the Use of Biosimilars in the United States
Jan 9th • 9 mins read
Report from American Society of Clinical Oncology Symposium 2020 and American Society of Clinical Oncology Gastrointestinal Cancer Symposium 2021
Aug 4th • 13 mins read